ArticleJournal of cancer research and clinical oncology2025
Immunotherapy with and without radiotherapy following the diagnosis of bone metastasis for stage IV non-small cell carcinoma.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiotherapy plus immune checkpoint inhibitors versus immune checkpoint inhibitors alone for non-small cell lung cancer with bone metastases: a systematic review and meta-analysis of comparative cohort studies.Frontiers in immunology · 2026Pooled it
- Commentary on early survival gains from adding radiotherapy to ımmunotherapy in bone-metastatic NSCLC.Journal of cancer research and clinical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis retrospective study compared the impact of radiotherapy (RT) and immunotherapy (IO) on survival in patients with stage IV non-small cell lung cancer (NSCLC) following a diagnosis of bone metastasis.
methodsThe TriNetX database (2013-2024) was queried for adults (≥ 18 years) with NSCLC who received IO after diagnosis of bone metastases. Patients were then divided into cohorts based on whether they also received RT after bone metastasis diagnosis.
resultsA risk assessment revealed RT + IO was associated with significantly improved survival at 3 months (92% vs. 86% alive, p < 0.001), 6 months (79% vs. 72%, p = 0.002), and 1 year (59% vs. 54%, p = 0.014). In patients with adenocarcinoma, RT + IO was associated with improved survival at 3 months (92% vs. 88%, p = 0.046) but not at 6 months or 1 year. Similarly, in patients with squamous cell carcinoma, IO + RT was also associated with higher survival (94% vs. 85%, p = 0.040) at 3 months but not at 6 months or 1 year. A Cox proportional hazards model found significant lower hazard of death in the RT + IO group (hazard ratio [HR] = 0.83) and several covariates were associated with higher hazard, including adrenal metastasis (HR = 1.7), liver metastasis (HR = 1.4), lymph node metastasis (HR = 1.3), hypoalbuminemia (< 3.45 g/dL; HR = 1.5), and inpatient or observation care (HR = 1.4). DISCUSSION: This study highlights the potential importance of combining RT with IO, particularly in the early period after bone metastasis diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.